Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United Parcel Service Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.88 (market cap $29.60B), while United Parcel Service Inc trades at $103.34 (market cap $88.85B). The key difference: United Parcel Service Inc is far larger — about 3× Alnylam Pharmaceuticals, Inc.'s market cap, and United Parcel Service Inc pays a 6.28% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | UPS | |
|---|---|---|
Market Cap | $29.60B | $88.85B |
Sector | Health | Industrials |
52-Week High | $491.22 | $120.00 |
52-Week Low | $205.48 | $82.58 |
Enterprise Value | $27.56B | $112.87B |
Volume | — | 2,288,643 |
Dividend Yield | — | 6.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
UPS trades at $104.71, up 0.22% on the day, with a bearish technical signal but strong fundamentals including a 29.66% ROE and consistent earnings beats. Revenue has declined from $100.3B in 2022 to $88.7B in 2025, though Q2 2026 showed a 7.6% YoY increase. The company maintains a solid dividend yield of 6.3% and is executing a strategic shift away from low-margin Amazon volume.
The outlook is mixed; analyst consensus is a Buy with a $117.90 price target, but technicals and declining net income pose risks. Opportunities include margin improvement from automation and healthcare logistics, while risks involve high dividend payout relative to free cash flow and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
